COLL, US19459J1043

Oppenheimer sets USD 50.00 target for Collegium Pharmaceutical stock

Published on 10/02/2026 at 13:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue reached USD 199.88 million, up 6.30 percent. Collegium Pharmaceutical stock costs EUR 19.65 on October 2, 2026 versus EUR 19.45.

COLL, US19459J1043, Illustration mit AI erstellt.

According to MarketBeat on September 23, 2026, Oppenheimer initiated coverage of Collegium Pharmaceutical (ISIN US19459J1043) with an Outperform rating and a USD 50.00 price target. Collegium Pharmaceutical was trading at EUR 19.65 at Lang & Schwarz on October 2, 2026 at 1:10 p.m. CEST, up 1.03 percent versus the prior close of EUR 19.45. The company now faces a market test of whether its ADHD expansion can offset pressure in older pain products.

Revenue beats expectations

Collegium reported second-quarter revenue of USD 199.88 million for the period ended June 30, 2026, up 6.30 percent from the same period a year earlier, according to MarketBeat. Reported earnings per share reached USD 1.92 versus a consensus estimate of USD 1.72, a USD 0.20 positive difference.

The finance statement for the second quarter also shows diluted earnings per share of minus USD 0.46 and net income attributable to common shareholders of minus USD 15.1 million. The contrast with the reported adjusted figure makes the accounting basis important when investors compare the quarterly headline with GAAP results.

ADHD growth meets pain pressure

At the H.C. Wainwright conference on September 16, 2026, management said the ADHD portfolio is becoming the main growth engine. According to Investing.com, Jornay PM revenue rose 41.00 percent year over year in the latest quarter, while total revenue increased 6.00 percent and adjusted EBITDA rose 8.00 percent.

The same presentation identified a concrete counterweight: generic competition has started to pressure the Nucynta franchise. Collegium also disclosed a USD 50.00 million accelerated share repurchase program in August 2026, while Astaris is expected to add to the ADHD portfolio after its 2026 acquisition.

EUR 19.65 in afternoon trading

At Lang & Schwarz, Collegium Pharmaceutical was trading at EUR 19.65 on October 2, 2026 at 1:10 p.m. CEST, plus 1.03 percent versus the prior close of EUR 19.45. Its USD 708.4 million market capitalization and USD 21.43 to USD 50.79 52-week range were dated October 1, 2026, while the next earnings release is expected on November 5, 2026, according to Zacks.